CG Oncology, Inc. - Common stock (CGON)
CGON moved a median of +0.14% 30 minutes after news, and +0.18% by the close. How CGON actually reacts to news — the realized, point-in-time move the market made, measured across 271 labeled events over the last three years with zero look-ahead.
CGON’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.20% | 57% | 271 |
| 30-min | +0.14% | 52% | 271 |
| 60-min | -0.16% | 48% | 271 |
| to close | +0.18% | 52% | 270 |
| Middle 50% of CGON reactions | -0.95% to +1.44% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 271 |
Half of all CG Oncology, Inc. - Common stock news events land between -0.95% and +1.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CGON reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +2.37% | 73% | 0.00% |
| Coverage initiations | 59 | -0.60% | 27% | -1.19% |
| Rating reiterations | 72 | -0.23% | 47% | -1.37% |
| Price-target raises | 13 | -0.53% | 31% | +0.21% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CGON ranks against every other measured name →
That’s how CGON usually reacts — get an email when it moves on news →Email me when CGON moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CGON's baseline. Nothing else.
Recent CGON events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer | Press release | GlobeNewswire | +0.73% | +0.61% | |
| CG Oncology to Present at Upcoming Investor Conferences in September | Press release | GlobeNewswire | +0.88% | -2.93% | |
| CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +5.71% | +3.81% | |
| Form 10-Q CG Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.71% | +3.81% | |
| Form 8-K CG Oncology, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +5.71% | +3.81% | |
| CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology | Press release | GlobeNewswire | -1.39% | -1.28% | |
| Form 8-K CG Oncology, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +2.08% | +1.67% | |
| CG Oncology to Present at Upcoming Investor Conferences in June | Press release | GlobeNewswire | +0.74% | +1.88% | |
| Form 8-K CG Oncology, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -3.13% | -3.30% | |
| SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award | Press release | GlobeNewswire | -1.22% | +1.88% | |
| CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | Press release | GlobeNewswire | +0.01% | -3.28% | |
| CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC | Press release | GlobeNewswire | -0.43% | +3.97% | |
| CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.62% | +1.04% | |
| Form 10-Q CG Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.58% | +1.46% | |
| Form 8-K CG Oncology, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +1.62% | +1.04% | |
| CG Oncology to Present at Upcoming Investor Conferences in May | Press release | GlobeNewswire | +0.81% | -2.13% | |
| Form ARS CG Oncology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.71% | -3.30% | |
| Form DEF 14A CG Oncology, Inc. For: Apr 23 | SEC filing · Form DEF | SEC EDGAR | +0.71% | -3.30% | |
| Form DEFA14A CG Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.71% | -3.30% | |
| Form 8-K CG Oncology, Inc. For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | +1.18% | |
| CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.71% | +5.39% | |
| Form 10-K CG Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.71% | +5.39% | |
| Form 8-K CG Oncology, Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | +5.39% | |
| Form S-8 CG Oncology, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.71% | +5.39% | |
| CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +2.72% | +2.19% | |
| Form 8-K CG Oncology, Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | +7.31% | |
| CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | Press release | GlobeNewswire | +7.93% | +22.74% | |
| Form 8-K CG Oncology, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +7.93% | +22.74% | |
| CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.66% | +1.51% | |
| SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award | Press release | GlobeNewswire | +2.16% | +1.31% | |
| New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer | Press release | GlobeNewswire | +1.43% | -3.88% | |
| CG Oncology Announces New Board Member and Board Transition | Press release | GlobeNewswire | -0.91% | -1.39% | |
| Form 8-K CG Oncology, Inc. For: Nov 22 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | -1.39% | |
| CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting | Press release | GlobeNewswire | -0.91% | -1.39% | |
| CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.32% | +7.86% | |
| Form 10-Q CG Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.50% | -0.43% | |
| Form 8-K CG Oncology, Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -0.43% | |
| Form 8-K CG Oncology, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +7.86% | |
| Form 8-K CG Oncology, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | -0.09% | |
| CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months | Press release | GlobeNewswire | -1.06% | +6.23% | |
| Form 8-K CG Oncology, Inc. For: Sep 05 | SEC filing · Form 8-K | SEC EDGAR | -1.06% | +6.23% | |
| CG Oncology Completes Enrollment in PIVOT-006 | Press release | GlobeNewswire | +1.66% | +5.95% | |
| CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.47% | +0.45% | |
| CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.33% | +2.05% | |
| Form 10-Q CG Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.38% | -3.25% | |
| Form 8-K CG Oncology, Inc. For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -0.33% | +2.05% | |
| Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals | Press release | GlobeNewswire | +0.02% | -3.89% | |
| Form 8-K CG Oncology, Inc. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | -0.39% | |
| Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs | Press release | Canada Newswire | +1.34% | +0.65% | |
| Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors | Press release | PR Web | +0.15% | +0.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CGON section they belong to.
Where else CGON is measured.
CGON earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CG Oncology, Inc. - Common stock's median reaction calculated?
Every labeled CGON news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 271 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of CGON's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CGON's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.